

BIBLIOGRAFÍA

1. Mahendra B. Dementia: A brief history of the concept. En: Mahendra B, ed. Dementia. Lancaster: MTP Press Limited 1987; 1-18.
2. J.M. Martínez Lage y P. Martínez-Lage Álvarez. Concepto, criterios diagnósticos y visión general de las demencias. En: S. López-Pousa, J. Vilalta y J. Llinás Reglá (Eds). Manual de Demencias. Barcelona.: Ed. Prous 1996; 14-44.
3. J.M. Martínez Lage y P. Martínez-Lage Álvarez. Concepto, criterios diagnósticos y visión general de las demencias. En: S. López-Pousa, J. Vilalta y J. Llinás Reglá (Eds). Manual de Demencias. Barcelona.: Ed. Prous 1996; 20.
4. J. Vilalta Franch. Consideraciones sobre el diagnóstico de las demencias. En: S. López-Pousa, ed. Actualización en demencias. Barcelona.: Ed. Prous 1995: 13.
5. J. Vilalta Franch. Consideraciones sobre el diagnóstico de las demencias. En: S. López-Pousa, ed. Actualización en demencias. Barcelona.: Ed. Prous 1995: 13-46.
6. American Psychiatric Association. DSM-III-R. Manual diagnóstico y estadístico de los trastornos mentales. Masson SA, Barcelona 1988.
7. Organización Mundial de la Salud (OMS). CIE-10. Décima revisión de la clasificación internacional de las enfermedades. Trastornos mentales y del comportamiento. Descripciones clínicas y pautas para el diagnóstico. División de Salud Mental, Ginebra. Meditor. Madrid 1992; 63-84.
8. A. López Munain. Epidemiología de las demencias. Rev. de Neurología, Julio 1997; 25 :44.
9. Jorm AF, Korten AE, Henderson AS. The prevalence of dementia: a quantitative gration of the literature. Acta Psychiatr Scand 1987;76:465-479.
10. Bermejo, F., Colmenarejo, C., Tejeiro et al. Prevalence of dementia in four districts of Madrid: A pilot study in old people. Neuroepidemiology 1993; 12:135.

11. Richie K, Kildea D. Is senile dementia “age related” or “ageing-related”?-evidence from meta-analysis of dementia prevalence in the oldest old. *Lancet* 1995; 346:931-934.
12. Lobo A., Saz P., Diaz JL., Marcos G., Morales F, Pérez MG, Gracia E, Pascual LF. The epidemiological study dementia in Zaragoza, Spain. En: Stefanis CN, Soldatos CR, Rabavilas AD, eds. *Psychiatry: a world perspective. Proceedings of the VIII World Congress of Psychiatry, Athens, oct. 13-19, 1989.* Amsterdam: Elsevier, 1990; 133-137.
13. Coria F, Gómez de Caso A, Minguéz L, Rodríguez-Artalejo F, Clavería LE. Prevalence of age-associated memory impairment and dementia in a rural community. *J. Neurol Neurosurg Psychiatry* 1993; 56:973-976.
14. López-Pousa S, Llinás J, Vilalta J. The prevalence of dementia in Girona. *Neurología* 1995; 10:189-193.
15. Manubens JM, Martínez-Lage JM, Lacruz F, Muruzabal J, Larumbe R, Guarch C, Uprutia T, Sarrasqueta P, Martínez-Lage P, Rocca WA. Prevalence of Alzheimer’s disease and other dementing disorders in Pamplona, Spain. *Neuroepidemiology* 1995; 14:155-164.
16. Launer LJ, Brayne C, Dartigues JF, Hofman A, eds. European studies on the incidence of dementing diseases. *Neuroepidemiology* 1992; 11:1-22.
17. Fratiglioni L, Launer LJ, Andersen K et al. “Incidence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts” *Neurology* 2000; 54:S10-S15.
18. Schoenberg BS, Anderson DW, Haerer AF. Severe dementia. Prevalence and clinical features in a biracial US population. *Arch Neurol* 1985; 42:740-743.
19. S. López-Pousa. Epidemiología de las demencias. En: S. López-Pousa, ed. *Actualización en demencias.* Barcelona Ed: Prous 1995; 1-12
20. Bermejo F. Epidemiología de la demencia. Revisión del tema y datos de España. *Rev. Clin Esp* 1987; 181:13-21.

21. Cummings JL, Benson DF. Dementia. A clinical approach. Second Edition. Woburn Londres, Butterworth, 1992.
22. JM. Manubens y F. Lacruz . Etiología de las demencias. En: F. Bermejo y T. Del Ser (Eds). Demencias: conceptos actuales. Ed: Diaz de Santos. Madrid 1993; 53-58.
23. JM. Manubens y F. Lacruz . Etiología de las demencias. En: F. Bermejo y T. Del Ser, eds. Demencias: conceptos actuales. Ed: Diaz de Santos. Madrid 1993; 55
24. JM. Manubens y F. Lacruz . Etiología de las demencias. En: F. Bermejo y T. Del Ser (Eds). Demencias: conceptos actuales. Ed: Diaz de Santos. Madrid 1993; 57
25. F. Bermejo. Manifestaciones clínicas y diagnóstico de la demencia. En: S. López-Pousa, J. Vilalta Franch y J. Llinás Reglá eds: Manual de Demencias. Ed: Prous. Barcelona 1996; 45-55.
26. Brayne C, Calloway P. Normal aging, impaired cognitive function, and senile dementia of the Alzheimer's type: A continuum? Lancet 1988; 2: 1265-1263.
27. J. Vilalta Franch. Consideraciones sobre el diagnóstico de las demencias. En S. López-Pousa: Actualización en demencias. Ed. Prous S.A. Barcelona 1995; 41.
28. T. del Ser Quijano, J.M. Morales y F. Bermejo. Evaluación del deterioro mental y la demencia. En: F. Bermejo y T. Del Ser (Eds).: Demencias: conceptos actuales. Ed: Diaz de Santos. Madrid 1993;13-51.
29. JM Pérez-Trullén y JV Lafuente. La reunión neurológica de 1906 en Tübingen y el primer caso de enfermedad de Alzheimer. Estudio crítico. Rev de Neurología. Barcelona.Octubre 1996; 24: 1283-1289.
30. S. López-Pousa y R. Lozano Fernández de Pinedo. Enfermedad de Alzheimer. En: S. López-Pousa, J.Vilalta Franch, J. Llinás Reglá,eds.: Manual de Demencias. Ed: Prous. Barcelona 1996; 384-406.
31. Schoenberg BS, Anderson DW, Haerer AF. Severe dementia. Prevalence and clinical features in a biracial US population. Arch Neurol. 1985; 42: 740-743.
32. A. Palao. Enfermedad de Alzheimer. En:J.Matías-Guiu, P.Casquero, JF. Horga, R. Blasco (Eds.): Demencias. Ed: Ferrer Internacional. Alcoy 1987; 117-119.

33. F. Bermejo. Epidemiología de la demencia en España: situación en 1989. En: A. Alfaro Giner, A. Palao Sanchez y J. Sancho Rieger (Eds): Neuroepidemiologia. Ed: MCR. Barcelona 1990; 20-27.
34. Bermejo F, Del Ser T. Demencia. En: Acarín N, Alvarez J, Perez J, Glosario de Neurología. Sociedad Española de Neurología MCR, S.A. 1989.
35. Jorm, AF.,Henderson, AS., Jacomb, PA. Regional differences in mortality from dementia in Australia: An analysis of death certificate data. Acta Psychiatr Scand 1989; 79:179-185.
36. Hy L., Keller DM. Prevalence of AD among Withes. A summary by levels of severity. Neurology 2000; 55: 198-204.
37. Corella, D., Talamante S.,Calatayud A. Estudio epidemiológico de la enfermedad de Alzheimer en España (1989-1986). Rev.Esp. Neurol. 1992;7:565-570.
38. Secundino López-Pousa. Definición y epidemiología de la enfermedad de Alzheimer. En: Alberca, R., López-Pousa, eds: Enfermedad de Alzheimer y otras Demencias. Ed: Panamericana. Madrid 2002: 147-154.
39. Heyman A, Peterson B., Fillenbaum G. y cols. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part XIV: Demographic and clinical predictors of survival ub oatuebts with Alzheimer's disease. Neurology 1996; 46: 656-660.
40. Launer LJ, Brayne C, Dartigues JF, Hofman A. European studies on the incidence of dementing diseases. Neuroepidemiology 1992; 11: 1 122.
41. van Dujin CM. Epidemiology of the dementias: recent developments and new approaches. J Neurol Neursunrg Ppsychiatry 1996; 60:478-488.
42. Rorsman B, Hagnell O, Lanke J. Prevalence and incidence of senile and multi-infarct dementia in the Lundby Study: a comparison between the time periods 1947-1957 and 1957-1972. Neuropsychobiology 1986;15:122-129.
43. Boothby H, Blizard R, Livingston G, Mann AH. The Gospel Oak Study stage III: The incidence of dementia. Psychobiol Med 1994;24:89-95.

44. Bachman DL, Wolf PA, Linn R, Knoefel JE, Coob J, Belanger A, White LR, D'Agostino RB. Incidence of dementia and probable Alzheimer's disease in a general population: The Framingham study. *Neurology* 1993;43:515-519.
45. Hendiré H., Ogunniyi A., May KS. Y cols. Incidence of Dementia and Alzheimer Disease in 2 communities. *JAMA*, 2001; 285: 739-747.
46. Fratiglioni L., Launer LJ., Andersen K. et al. Incidence of dementia and major subtypes in Europe: a collaborative study population-based cohorts. *Neurology*, 2000; 54: S10-S15.
47. Kawas C., Gray S., Brookmeyer R et al. Age-specific incidence rates of Alzheimer's disease. The Baltimore Longitudinal Study of Aging. *Neurology*, 2000; 54: 2072-2077.
48. Dartigues JF., Gagnon M., Mazaux JM., Barberger-Gateua P., Commenges D., Ltenneur L., Orgogozo JM. Occupation during life and memory performance in nondemented French elderly community residents. *Neurology* 1992; 42: 1697-1701.
49. Katzman R. Education and the prevalence of dementia an Alzheimer's disease. *Neurology* 1993; 43: 138-145.
50. Plasman BL, Welsh KA, Helms M et al. Intelligence and education as predictors of cognitive state in late life: a 50-year-follow-up. *Neurology*, 1995; 45: 1446-1450.
51. F. Moya, J.R., Cerezo y C. Alberto. Patología celular y molecular en la enfermedad de Alzheimer (1988). En: J. Matías-Guiu, P. Casquero, J.F. Horga y R. Blasco (Eds). *Demencias*. MCR. Barcelona 1988; 139-154.
52. Rossor MN, Fox NC, Beck J y cols. Incomplete penetrance of familial Alzheimer's disease in a pedigree with a novel presenilin-1 gene mutation. *Lancet*, 1996; 347: 1560.
53. Wendham PR, Price WH, Blundell G. Apolipoprotein E genotyping by one stage PCR. *Lancet* 1991;337:1158.9.

54. Higgins GA, Large CH, Rupnik HT, Barnes JC. Apolipoprotein E and Alzheimer's disease: a review of recent studies. *Pharmacol Biochem Behav* 1997; 56:675-85.
55. M. Baiget Bastús . Aspectos neurogenéticos. En: S. López-Pousa, J. Vilalta Franch, J. Llinás Reglá (Eds): *Manual de demencias*. Barcelona. Ed. Prous 1996;109-112.
56. Martínez-Lage JM., Manubens JM., Lacruz F., Urrutia T., Sarrasqueta P., Guarch C., Muruzabal J., Larumbe J., Martínez-Lage P. Risk factors for Alzheimer's disease: case-control study in Pamplona. *Neurology* 1992; 42 :141.
57. W.A. van Gool, Evenhuis HM, van Dujin CM et al. A case-Control Study of Apolipoprotein E Genotypes im Alzheimer's Disease Associated with Down's Syndrome. *Arch Neurol* 1995 Aug; 38:225-30.
58. Tol J., Roks G, Slooter AJC et al. Genetic and environmental factors in Alzheimer's disease. *Rev. Neurol* 1999; 155: 10-16.
59. A. López de Munain. Demencias por priones: un nuevo paradigma patogénico. *Rev. de Neurol.* 1997; 25 : 56.
60. W.H. Rocca: Epidemiología de la enfermedad de Alzheimer: una actualización. . En: F. Bermejo y T. Del Ser (Eds.). *Demencias: conceptos actuales*. Madrid. Ed.: Díaz Santos 1993.: 89.
61. Martyn CN., Barker DJP., Osmond C., Harris EC., Edwarson JA., Lacey RF. Geographical relation between Alzheimer's disease and aluminium in drinking water. *Lancet* 1989; 1:59-62.
62. Friedlan RP. Epidemiology, education, and the ecology of Alzheimer's disease. *Neurology* 1993; 43: 246-249.
63. Schofield PW, Tang M, Marder K y cols. Alzheimer's disease afer rote head injury: a incidece sudy. *J Neurol Nerosurg Pshiry* 1997, 62:119-24.
64. Davies, P., Maloney, AJF. Selective loss of central cholinergic neurons in Alzheimer's disease. *Lancet* 1976; 2: 1403.

65. Beal MF., Mazurek MF., Tran VJ., Chattha G., ED y Nartin JB. Reduced numbers of omatostatin receptors in the cerebral cortex in Alzheimer's disease. *Science* 1985; 229: 289-291.
66. Dewarrd D, McCulloch J. Abnormalities in non-cholinergic neurotransmitters systems in Alzheimer's diseases. En: Burns A, Levy R (Eds.). *Dementia*. London: Chapman Hall, 1994; 159-183.
67. Greenamyre JT., Penney JB., D'Amato CJ., Young AB. Dementia of the Alzheimer's type: changes in hippocampal L-3 H-glutamate binding. *Neurochem* 1985; 48: 543-551.
68. JF. Horga. Neurofarmacología de la enfermedad de Alzheimer. En: J. Matías-Guiu, P. Casquero, JF. Horga y R. Blasco. (Eds.): *Demencias*. MCR Barcelona. 1988;157-169.
69. J. Lamarca, T. Ribalta. Neuropatología de la enfermedad de Alzheimer. En: J. Matías-Guiu, P. Casquero, JF. Horga y R. Blasco. Eds.: *Demencias*. MCR Barcelona. 1988; 173-179.
70. I. Ferrer Abizanda. Neuropatología de las demencias. En En: S. López-Pousa, J.Vilalta Franch, J. Llinás Reglá (Eds): *Manual de Demencias*. Ed: Prous. Barcelona 1996; 117
71. Schneider LS. New therapeutic approaches to Alzheimer's disease. *J Clin Psychiatry* 1996;57:30.6.
72. AR Pryse, Phillips W. Do we have drugs for dementia? *Arch Neurol* 1999;56:735.7.
73. Glenner GG. Alzheimer's disease. The commonest form of amyloidosis. *Arch Pathol Lab. Me* 1983; 107: 281-282.
74. Teresa Gómez-Isla, Richard Hollister BA, Howard West MD, Stina Mui BA, John H. Growdon MD, Ronald C. Petersen, MD et al. Neuronal Loss Correlates with but Exceeds Neurofibrillary Tangles in Alzheimer's Disease. *Annals of Neurology* 1997; 41: 17-24.

75. Kimmo Hatanpää, Daniel R. Brady, James Stoll, Stanley I, Rapoport and Krish Chandrasekaran. Neuronal Activity and Early Neurofibrillary Tangles in Alzheimer's Disease. *Annals of Neurology* 1996; 40: 411-420
76. R. Motter, C. Vigo-Pelfrey, Khloenko D, Barbour R, Jonson-Wood K, Galasco D, Chang L, Miller B, Clark C, Green R, et al. Reduction of B-Amyloid Peptide 42 in the Cerebrospinal Fluid of Patients with Alzheimer's Disease. *Annals of Neurology* 1995 Oct; 38: 643-648
77. D.M. A. Mann, T. Iwatsubo, Nochlin D Sumi SM, Levy-Lahad E, Bird TD. Amyloid (AB) Deposition in Cromosoma 1-linked Alzheimer's Disease: The Volga German Families. *Annals of Neurology* 1997 Jan; 41: 52-57
78. Xiaohua Chen, Yu Xia Alford M, De Teresa R, Hansen L, Klauber MR, Katzman R, Thal L, Masiliah E, Sayito T. The CYP2D6B Allele is Associated with a Milder Synaptic Pathology in Alzheimer's Disease. *Annals of Neurology* 1995 Oct; 38: 653-658.
79. Pericak-vance MA, Jonson CC, Rimmier JB, Saunders AM, Robinson LC, D'Hondt EG, Jackson CE, Haines JL. Alzheimer's Disease and Apolipoprotein E-4 allele in amish Population. *Annals of Neurology* 1996 Jun; 39: 700-704.
80. Ferre, I. Morfopatología de la enfermedad de Alzheimer. En: Alberca, R., López-Pousa (Eds): *Enfermedad de Alzheimer y otras Demencias*. Ed: Panamericana. Madrid 2002: 179-193.
81. Hamos JE, Degennaro LJ, Drachman DA. Synaptic loss in Alzheimer's disease and other dementias. *Neurology* 1989; 39: 355-361.
82. Mckann, G., Drachman, D., Foltein, M. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. *Neurology* 1984; 34: 939-944.
83. Francis PT, Palmer AM, Snape M, Wilcock GK. The cholinergic hypothesis of Alzheimer's disease: a review of progress. *J Neurol Neurosurg Psychiatry* 1999;66:137-147.

84. Bartus RT, Dean RL, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. *Science* 1982;217:408-414.
85. D. E. Jul, S. Minoshima, J.A. Fessler, K.A. Frey, N. L. Foster, E.P. Ficaró, et al. In vivo Mapping of Cholinergic Terminals in Normal Aging, Alzheimer's Disease, and Parkinson's Disease. *Annals of Neurology* 1995; 40,3: 399-410.
86. Hiroyuki Arai, Masaróni Terajima, Msakazu Miura, Susumu Higuchi, Taro Muratmatsu et al. Tau in Cerebrospinal Fluid: A Potential Diagnostic Marker in Alzheimer's Disease. *Annals of Neurology* 1995; 38:649-652.
87. Davies P., Maloney, AJ. Selective loss of central cholinergic neurons in Alzheimer's disease (Letter) *Lancet* 1976; 2: 1403.
88. Rossor, MN. Dementia. *Lancet* 1983; 2:292-296.
89. Perry EK, Tomlinsin BE, Blessed G et al. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. *Br Med J* 1978; 2:1457-1459.
90. Lawrence AD, Sahakian BJ. The cognitive psychopharmacology of Alzheimer's disease: focus on cholinergic systems. *Neurochem Res* 1998;23:787-94.
91. Shimohama S, Taniguchi T, Fujiwara M, Kameyama M. Changes in nicotinic and muscarinic cholinergic receptors in Alzheimer-Type Dementia. *J Neurochem* 1986 Jan; 46:288-93.
92. Flynn DD. Characterization of L3 H-Nicotine Binding in human cerebral cortex: Comparison between Alzheimer's disease and the Normal. *J Neurochem*. 1986; 47:1948-1954.
93. Albuquerque EX, Alkondon M, Pereira EF, Castro NG, Schratzenholz A, Barbosa CT, et al. Properties of neuronal nicotinic acetylcholine receptors: pharmacological characterization and modulation of synaptic function. *J Pharmacol Exp Ther* 1997;280:1117-36.
94. Appleyard ME, Smith AD, Wilcock GK, Esiri MM. Decreased CSF acetylcholinesterase activity in Alzheimer's disease. *Lancet* 1983 Aug 20; 2:452.

95. Mann DM, Lincoln J, Yates PO, Stamp JE, Toper S. Changes in the monoamine containing neurones of the human CNS in senile dementia. *Br J Psychiat* 1980 Jun; 136:533-41.
96. Yates CM., Ritchie IM., Simpson J., Maloney AFJ., Gordon A. Noradrenaline in Alzheimer-type dementia and Down Syndrome. *Lancet* 1981; 2: 39-40.
97. S. López-Pousa, R. Lozano Fernandez de Pinedo. Enfermedad de Alzheimer. En S. López-Pousa, J. Vilalta Franch, J.Llinás Reglá (Eds). *Manual de demencias*. Barcelona. Prous S.A. 1996; 401.
98. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS/ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. *Neurology* 1984;34:939-44.
99. Adam A. Aspectos psicosociales de la enfermedad somática: acontecimientos de la vida. Tesis de licenciatura. Valencia 1984.
100. Hachinski V, Lassen NA, Marshall J. "Multi-infarct dementia: A cause of mental deterioration in the elderly". *Lancet*, 1974; ii:207-210.
101. J. Vilalta Franch. Consideraciones sobre el diagnóstico de las demencias. En S. López-Pousa: *Actualización en demencias*. Ed. Prous S.A. Barcelona 1995; 36.
102. Llinás Reglá. Valoración neuropsicológica de la demencia. En S. López-Pousa, J. Vilalta Franch, J.Llinás Reglá, ed. *Manual de demencias*. Barcelona. Prous S.A. 1996; 153.
103. Van Elteren PH. On the combination of independent two sample tests of Wilcoxon. *Bull Inst Intern Statist* 1960; 37:351.61.
104. T. Del Ser Quijano, J. Peña-Casanova. Objetivos y métodos en la evaluación de la demencia. En: T. Del Ser Quijano, J. Peña-Casanova. *Evaluación neuropsicológica y funcional de la demencia*. Barcelona. Prous S.A. 1994; 1-7.
105. J. Peña-Casanova, I. Beltrán-Serra y T. Del Ser Quijano. Evaluación neuropsicológica de la demencia. En: T. Del Ser Quijano, J. Peña-Casanova.

- Evaluación neuropsicológica y funcional de la demencia. Barcelona. Prous S.A. 1994; 9-48.
106. J. Vilalta Franch. Neuropsicología de las demencias. En S. López-Pousa: Actualización en demencias. Ed. Prous S.A. Barcelona 1995; 52.
107. J.M. Morales González y T. Del Ser Quijano. Escalas de detección del deterioro mental en el anciano. En: T. Del Ser Quijano, J. Peña-Casanova (Eds.). Evaluación neuropsicológica y funcional de la demencia. Barcelona. Prous S.A. 1994; 76.
108. Folstein MF, Folstein SE, McHugh PR. Mini-Mental State. A practical method for grading the cognitive state of patients for the clinician, *J Psychiat Res* 1975 Nov; 12: 189-98.
109. F. Bermejo Pareja y T. Del Ser Quijano. La graduación de las demencias y su estudio evolutivo. En: T. Del Ser Quijano, J. Peña-Casanova. Evaluación neuropsicológica y funcional de la demencia. Barcelona. Prous S.A. 1994; 189.
110. Rosen, WG, Mohs R.C., Davis K.L. A new rating scale for Alzheimer's disease. *Am J Psychiatr* 1984; 141: 1356-1364.
111. Welsh, K.A., Butters, N., Hughes, J.P., et al. Detection and staging of dementia in Alzheimer's disease. Use of the neuropsychological measures developed for the Consortium to Establish a Registry for Alzheimer's Disease. *Arch Neurol* 1992; 49: 448-452.
112. Moss MB, Alber MS. Neuropsychology of Alzheimer's disease. En: White. R.F. (Ed.). *Clinical syndromes in adult neuropsychology: The practitioner's handbook*. Elsevier 1992.
113. Joannette Y, Belleville S, Lecours AR, Peretz I, Poissant A, Ska B. The neuropsychological assessment in studies on dementia. *The Optimal Approach* 1992.
114. Y. Joannette, S. Belleville, A. Roch Lecours, I. Peretz, A. Poissant y B. Ska. Evaluación neuropsicológica de la demencia: sistemática óptima. En: T. Del Ser Quijano, J. Peña-Casanova. Evaluación neuropsicológica y funcional de la

- demencia. Barcelona. Prous S.A. 1994;121.
115. J. Llinás Reglá. Valoración neuropsicológica de la demencia. En S. López-Pousa, J. Vilalta Franch, J.Llinás Reglá, ed. Manual de demencias. Barcelona. Prous S.A. 1996;160.
116. J.J. Baztán Cortés, J.I. González Montalvo y T. Del Ser Quijano. Escalas de actividades de la vida diaria. En: T. Del Ser Quijano, J. Peña-Casanova. Evaluación neuropsicológica y funcional de la demencia. Barcelona. Prous S.A. 1994; 137-164.
117. Baumgarten M, Becker R. Validity and reliability of the Dementia Behavior Disturbance scale. *J am Geriatr Soc* 1990; 38: 221-226.
118. Lawson JS, Rodenburg m. Dementia Rating Scale for use with psychogeriatric patients. *J Gerontol* 1977; 32: 153-159.
119. Jorm AF, Korten E. Assessment of cognitive decline in the elderly by informant interview. *Br J psychiatr* 1988; 152: 209-213.
120. J.M. Morales González y T. Del Ser Quijano. Escalas de detección del deterioro mental en el anciano. En: T. Del Ser Quijano, J. Peña-Casanova. Evaluación neuropsicológica y funcional de la demencia. Barcelona. Prous S.A. 1994 ; 84.
121. Shader RI, Hartz JS y col. A new scale for clinical assessment in geriatric populations: Sandoz Clinical Assessment-Geriatric (SCAG). *J Am Geriatric Soc* 1974; 22: 107-113
122. Llinás, J., Vilalta, J., López-Pousa, S., Amiel, J., Vial, C. CAMDEX.. Validación de la adaptación española. *Neurología* 1990; 5: 117-120.
123. Llinás, J., Vilalta, J., López-Pousa, S., Amiel, J., Vial, C. CAMDEX.. Fiabilidad interexaminadores en la adaptación española. *Neurología* 1990; 5: 120-122.
124. Hamilton M,. A rating scale for depression. *J Neurol Neurosug Psychiatr* 1960; 23:361-366.
125. Yesavage, JA et al. Development and validation of a geriatric depression screenig scale: A preliminary report. *J Psychiat* 1983; 17: 37-49

126. Reisberg B, Ferris SH et al. The Global Deterioration Scale for assessment of primary degenerative dementia. *Am J Psychiatr* 1982; 139:1136-1139.
127. Berg, J. The clinical Dementia Rating (CDR) of Washington University. *Psychopharmacol Bull* 1988; 24:637-639.
128. Pryse-Phillips W. Do we have drugs for dementia? *Arch Neurol* 1999; 56:735-737.
129. Rosenberg RN. The molecular and genetic basis of AD: The end of the beginning. The 2000 Wartenberg lecture. *Neurology*, 2000; 54: 2045-20-54.
130. MacGowan SH, Wilcock G, Scott M. Effect of gender and apolipoprotein E genotype on response to acetylcholinesterase therapy in Alzheimer's disease. *Int J Geriatr Psychiatr* 1998;13:625.30.
131. Ott a, Stolk RP, van Harskamp F y cols. Diabetes mellitus and the risk of dementia. The Rotterdam study. *Neurology*, 1999; 53: 1937-1942.
132. Allen NHP, Burns A. The treatment of Alzheimer's disease. *J Psychopharmacol* 1995; 9:43.56.
133. Dubois B, McKeith I, Orgogozo J.M, Collins O, Meulien D, MALT Study Group. A multicentre, randomized, double-blind, placebo-controlled study to evaluate the efficacy, tolerability and safety of two doses of metrifonate in patients with mild to moderate Alzheimer's disease: the MALT study. *Int J Geriatr Psychiatry* 1999;14:973.82.
134. Farlow MR, Cyrus PA, Nadel A, Lahiri DK, Brashear A, Gulanski B. Metrifonate treatment of AD: influence of APOE genotype. *Neurology* 1999; 53:2010-2016.
135. Food and Drug Administration. Peripheral and central nervous system drugs advisory committee meeting, July, 1989. Rockville, MD: Department of Health and Human Services, Public Health Service, 1989:227.
136. Knapp MJ, Knopman DS, Solomon PR, Pendlebury WW, Davis CS, Gracon SI. A 30 week randomized controlled trial of high dose tacrine in patients with Alzheimer's disease. *JAMA* 1994; 271:985-991

137. Farlow MR, Lahiri DK, Poirer J, Davignon J, Hui SL. Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer's disease. *Neurology* 1998; 50:669.77.
138. Rogers SL, Doody RS, Mohs RC, Friedhoff LT, Donepezil Study Group. Donepezil improves cognition and global function in Alzheimer disease. *Arch Intern Med* 1998; 158:1021-1031.
139. Committee for Proprietary Medicinal Products. Note for guidance on medicinal products in the treatment of Alzheimer's disease. London: European Agency for the Evaluation of Medicinal Products, 1997.
140. Nordberg A, Svensson A.L. Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology. *Drug Saf* 1998; 19:465.80.
141. Schneider LS. New therapeutic approaches to Alzheimer's disease. *J Clin Psychiatry* 1996;57:30.6.
142. Alberca R. Tratamiento de la enfermedad de Alzheimer. En: Alberca R (ed.). *Demencias. Diagnóstico y tratamiento*. Madrid: Editorial Masson, 1998; 159-182.
143. Rogers SL, Friedhoff LT, Donepezil Study Group. The efficacy and safety of donepezil in patients with Alzheimer's disease: results of US multi. centre, randomized, double.blind, placebo.controlled trial. *Dementia* 1996;7:293-303
144. Rogers SL, Doody RS, Mohs RC, Friedhoff LT, Donepezil Study Group. Donepezil improves cognition and global function in Alzheimer disease. *Arch Intern Med* 1998;158:1021-1031
145. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT, Donepezil Study Group. A 24.week, double.blind, placebo.controlled trial of donepezil in patients with Alzheimer's disease. *Neurology* 1998; 50:136.45
146. Burns A, Rossor M, Hecker J, Gauthier S, Petit H, Möller H.J, et al. The effects of donepezil in Alzheimer's disease—results from a multinational trial. *Dement Geriatr Cogn Disord* 1999;10:237.44

147. Bentham P, Gray R, Sellwood E, Raftery J. Effectiveness of rivastigmine in Alzheimer's disease. *BMJ* 1999; 319:640
148. Cutter NR, Polinsky RJ, Sramek JJ et al. "Dose-dependent CSF acetylcholinesterase inhibition by SDZ ENA 713 in Alzheimer's disease". *Acta Neurol Scand*, 1998; 97:244-250.
149. Corey.Bloom J, Anand R, Veach J, ENA 713 B352 Study Group. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. *Int J Geriatr Psychopharmacol* 1998; 1:55.65
150. Rösler M, Anand R, Cicin.Sain A, Gauthier S, Agid Y, Dal.Bianco P, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. *BMJ* 1999; 318:633.8
151. Cuttler NR, Veroff AE, Anad R et al. Correlation between cognitive effects and level of acetylcholinesterase inhibition in a trial of rivastigmine in Alzheimer patients. *Neurology* 1999; 52 : A 173.
152. Bores GM, Huger FP, Petko W, Mutlib AE, Camacho F, Rush DK, et al. Pharmacological evaluation of novel Alzheimer's disease therapeutics: acetylcholinesterase inhibitors related to galanthamine. *J Pharmacol Exp Ther* 1996; 277:728.38
153. Gordon K Wilcock, Sean Lilienfeld, Els Gaens on behalf of the Galantamine International.1. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial Study Group. *BMJ* 2000; 321:1-7
154. Tariot P, Solomon P, Morris J, Kershaw P, Lilienfeld S, Parys W, et al. A 5 month, randomized, placebo controlled study of galantamine in AD. *Neurology* 2000; 54:2269-2276
155. Vasilenko ET, Tonkopii VD. Characteristics of galanthamine as a reversible inhibitor of cholinesterase. *Biokhimiia* 1974; 39:701.3.

156. MacGowan SH, Wilcock G, Scott M. Effect of gender and apolipoprotein E genotype on response to acetylcholinesterase therapy in Alzheimer's disease. *Int J Geriatr Psychiatr* 1998;13:625-30.
157. J.M. Martínez-Lage y P. Martínez-Lage Álvarez. Posibilidades terapéuticas en la enfermedad de Alzheimer. En S. López-Pousa (Ed). *Actualización en demencias*. Barcelona. Ed. Prous S.A. 1995; 190.
158. Luis F. Pascual Millán. II Curso Nacional de Enfermedad de Alzheimer. Madrid, marzo,1997.
159. Gelinas I, Gauthier L, McIntyre M, Gauthier S. Development of a functional measure for persons with Alzheimer's disease: the disability assessment for dementia. *Am J Occup Ther* 1999; 53:471-81.
160. T. Del Ser. Tratamientos conductuales en la enfermedad de Alzheimer. En: N. Acarín Tusell, J. Alom (Eds). *Marcadores biológicos y perspectivas terapéuticas en la enfermedad de Alzheimer*. Barcelona. Ed. MCR, S.A. 1989; 129-136.
161. Tárrega L. Terapias Blandas: Programa de Psicoestimulación integral. Alternativa terapéutica para las personas con enfermedad de Alzheimer. *Rev. Neurol.*, 1998; 27: S51-S62.
162. M. Izal Fernández e I. Montorio Cerrato. Evaluación del medio y del cuidador del demente. En: T. Del Ser Quijano, J. Peña-Casanova. *Evaluación neuropsicológica y funcional de la demencia*. Barcelona. Prous S.A. 1994 ; 215.
163. J.M. Martínez-Lage y P. Martínez-Lage Álvarez. Posibilidades terapéuticas en la enfermedad de Alzheimer. En S. López-Pousa (Ed). *Actualización en demencias*. Barcelona. Ed. Prous S.A. 1995; 203
164. J. Peña-Casanova. Neuropsicología de las demencias. En: S. López Pousa (Ed.). *Actualización en demencias*. Prous S.A. 1995; 47-72.
165. Blessed, G., Tomlinson, BE., Roth, M. The associatt between quantitative measures of dementia and of senile changes in the cerebral grey matter of elderly subjects. *Br J Psichiatr* 1968; 114: 797-811.

166. Hachinski VC, Illif LD, Zilkha E et al. Cerebral blood flow in dementia. *Arch Neurol* 1975; 32:632-637.
167. Kavas C., Brookmeyer R. Aging and the Public Health Effects of Dementia. *N Engl. J Med*, 2001; 334: 1160-1161.
168. Boada M y cols. Pla Integral de la Gent Gran de Catalunya. Recull de Treballs Comité D'experts. Barcelona : Publicación Generalitat de Catalunya 1990 ; 4 : 187-221.
169. Yaakov Stern, Marshall Folstein, Marilyn Albert, Marcus Richards, Lisa Miller, Fred Bylsma et al. Multicenter Study of Predictors of Disease Course in Alzheimer's Disease (the "Predictors Study"). I. Study Design, Cohort Description, and Intersite Comparisons. *Alzheimer Disease and Associated Disorders* 1993; 7: 3-21.
170. Marcus Richards, Marshal Folstein, Marilyn Albert, Lisa Miller, Fred Bylsma, Ginette Lafleche et al. Multicenter Study of Predictors of Disease Course in Alzheimer's Disease (the "Predictors Study"). II. Neurological, Psychiatric, and Demographic Influences on Baseline Measures of Disease Severity. *Alzheimer Disease and Associated Disorders* 1993; 7: 22-32.
171. Yaakov Stern and Diane M. Preliminary Finding from the Predictors Study: Utility of Clinical Signs for Predicting Disease Course. *Alzheimer Disease and Associated Disorders* 1995, 9: S14-S18.
172. Charles Flicker, Steven H, Ferris, Barry Reisberg. A Two-Year Longitudinal Study of Cognitive Function in Normal Aging and Alzheimer's Disease. *Journal of Geriatric Psychiatry and Neurology* 1993; 6: 84-96.
173. Mölsä PK, Marttila RJ, Rinne UK. Long-term survival and predictors of mortality in Alzheimer's disease and multi-infarct dementia. *Acta Neurol Scand* 1995; 91: 159-164.
174. Linn-RT, Wolf PA, Bachman DL, Knoefel JE, Cobb JL, Balanger AJ et al. The preclinical phase of probable Alzheimer's disease. A 13 year prospective study of the Framingham cohort. *Arch Neurol* 1995; 52: 485-490.

175. SM Moran, L.L. Cockram, B. Walker and FM McPeherson. Prediction of survival by the Clifton Assessment Proceduras for the Elderly (CAPE). *British J of Clinical Psychology*, 1990; 29: 225-226.
176. Nielsen H, Lolk A, Pedersen I, Autzen M, Sennef C, Kragh-Sorensen P. The accuracy of early diagnosis and predictors of death in Alzheimer´s disease and vascular dementia – a fallow – up study. *Acta Psychiatri Scand* 1991 ; 84: 277-282.
177. Vetter P, Steiner O, Kraus S. et al. Factors affecting the utilization of homecare supports by caregiving relatives of Alzheimer´s patients. *Dement Geriatr Cogn Disord*, 1998; 9: 111-116.
178. Winslow BW. Family caregiving and the use of formal community support services: a qualitative case study. *Issues Ment Health Nurs*, 1998; 19: 11-27.
179. M. Aguilar-Barberá. Estudios de calidad de vida en el marco de las demencias. *Rev. Neurol* 1998; 28: S80-S84.
180. Helmer C, Joly P, Letenneur L, Commenges D, Dartigues JF. Mortality with dementia: results forma a French prospective community-based cohort. *Am J Epidemiol* 2001; 154: 642-8.
181. Gambassi G, Landi F, Lapane KL, Sgadari A, Mor V, Bernabei R. On behalf of the SAGE study group. Predictors of mortality in patients with Alzheimer´s disease living in nursing homes. *J Neurol Neurosurg Psychiatry* 1999; 67: 59-65.
182. Alistair Burns, Mphil, Robin Jacoby, Raymond Levy. Progression of Cognitive Impairment in Alzheimer´s Disease. *J Am Geriatr Soc*, 1991; 39: 39-45.
183. James T., F. Jacob, Robert D. Neves, Audrey Holland, François Boller. Neuropsychological Function in Alzheimer´s Disease. *Arch Neurol*, 1988, 45: 263-268.
184. Yaakov Stern, Ming Xi Tang, Jean Denaro, Richard Mayeux. Increased Risk of Mortality in Alzheimer´s Disease Patients with More Advanced Educational and Occupational Attainment. *Annals of Neurology* 1995, 37: 590-595.

185. Fischer P, Gatterer G, Marterer A, Simanyi M, Danielezyk W. Course characteristics in the differentiation of dementia of the Alzheimer type and multi-infarct dementia. *Acta Psychiatr Scand*, 1990 ; 81: 551-553.
186. WA. Kukull, EB Larson, L Teri, J Bowen, W McCormick, ML Pfanschmidt. The Mini-Mental State Examination score and the clinical diagnosis of dementia. *J Clin Epidemiol*, 1994 ; 47: 1060-1067.
187. Tombaugh, T.M. Mcintyre, N.J. The Mini-Mental State Examination: A comprehensive review. *J Am Geriatr Soc* 1992; 40: 922-935.
188. Peña-Casanova J. Normalidad, semiología y patología neuropsicológicas. Programa Integrado de Exploración Neuropsicológica. Test Barcelona. Barcelona: Mason, 1991.
189. Blessed, G. Tomlinson, Be., Roth, M. The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly sujetos. *J. Psychiatr* 1968; 114: 797-811.
190. Robert G. Stern, Richard C, Mohs, Linda M. Bierer, Jeremy M. Silverman, James Schmeidler et al. Deterioration on the Blessed Test in Alzheimer's Disease Longitudinal Data and Their Implication for Clinical Trials and Identification of Subtypes. *Psychiatry Resch* 1992, 42: 101-110.
191. Lopez-Pousa S, Mercadal J, Secades JJ, Lozano M, Marti AM, Vilata J, Lozano R. A new method for quantifying the cognitive impairment. Its application in patients with vascular dementia. *Neurologia* 1997; 12: 339-42.
192. Linda Teri, James P, Eric B. Cognitive Deterioration in Alzheimer's Disease: Behavioral and Health Factors. *J. Gerontology*, 1990; 45 : 58-63.
193. George Rebok, Jason Brandt, Marshal Folstein. Longitudinal Cognitive Declive in Patients With Alzheimer's Disease. *J of Geriatric Psychiatry and Neurology*, 1990; 3: 91-97.
194. David A. Drachman, O'Donnell BF, Lew RA, Swearer JM. The Prognosis in Alzheimer's Disease. *Arch Neurol*, 1990 Aug; 47:851-56.

195. Florence Lai, Roger S. A Prospective Study of Alzheimer's Disease in Down Syndrome. *Arch Neurol*, 1989; 46: 849-853.
196. Barclay LL, Zemcov A, Blass JP, McDowell FH. Factors associated with duration of survival in Alzheimer's disease. *Biological Psychiatry* 1985; 20: 86-93.
197. C. Carnero-Pardo. Educación, demencia y reserva cerebral. *Rev. Neurol* 2000; 31: 584-592.
198. Haupt M, Pollmann S. Kurz A. Symptom progression in Alzheimer's disease: relation to onset age and familial aggregation. *Acta Neurol Scand*, 1993; 88: 349-353.
199. Joan M Swearer, Brian F O'Donnell, Susan M Ingram, David . Drachman. Rate of Progression in Familial Alzheimer's Disease. *Psychiatry Neurol*, 1996; 9: 22-25.
200. Oscar L. López, François Boller, James T. Becker, Mark Miller, Charles F. Reynolds. Alzheimer's Disease and Depression: Neuropsychological Impairment and Progression of the Illness. *Am J Psychiatry*, 1990; 147: 855-860.
201. Bracco L, Gallato R, Grigoletto F, Lippi A, Lepore V, Bino G et al. ii Factors affecting course and survival in Alzheimer's disease. *Arch Neurol* 1994; 51: 1213-1219.
202. M.V. Perea, V. Ladera. Interacción entre el déficit neuropsicológico en ejecución y la competencia en las actividades cotidianas en la demencia tipo Alzheimer. *Rev. Neurol* 1997; 25: 513-518.
203. Morris, J., Heyman A., Mohs RC. Et al. The consortium to establish a registry for Alzheimer's disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease. *Neurology* 1989; 39: 1159-1165.
204. J.L. Carreras, MJ Pérez, R. Montz. PET y SPET en la enfermedad de Alzheimer. *Centro Pet Complutense* 1996;1: 89-103.
205. John D., W. Greene. Neuropsychology of memory and SPECT in the diagnosis and staging of dementia of Alzheimer type. *J Neurol*, 1996; 243: 175-190.

206. Herholtz K, Adams R. Criteria for the diagnosis of Alzheimer's disease with positron emission tomography. *Dementia*, 1990; 1: 156-164.
207. Brenner R., Ulrich RF. Et al. Computerized EEG spectral analysis in elderly normal demented and depressed subjects. *Electroencephalogr Clin Neurophysiol* 1986; 64: 483-492.
208. F. Bermejo, T. Gómez-Isla, JM Morales. El Mini-Mental State Examination en la evaluación del deterioro cognitivo y la demencia. En: *Evaluación neuropsicológica y funcional de la demencia*. T del Ser y J. Peña, eds. JR Prous Eds. Barcelona, 1994.
209. Botwinick J, Storandt M, Berg L. A longitudinal behavioral study of senile dementia of the Alzheimer type. *Archives Neurology* 1986; 43: 1124-1127.
210. Kaplan, E. , Fein F et al. WAIS-R as a neuropsychological instrument. Psychological Corp., New York 1991.
211. Weschler D. Manuel de l'échelle clinique de mémoire de D. Weschler. Ed. Centre de Psychologie Appliquée, Paris 1969.
212. Alexander I. Tröster, Michael V, Vitiello, Patricia N. Prinz. Predicting Long-Term Outcome in Individuals at Risk for Alzheimer's Disease With the Dementia Rating Scale. *J. of Neuropsychiatry* 1994; 6: 54-56, 1994.
213. F. Bermejo, T del Ser. La graduación de las demencias y su estudio evolutivo. En *Evaluación neuropsicológica y funcional de la demencia*. T del Ser y J. Peña (Eds). JR Prous Eds. Barcelona 1994;179-199.
214. Freels S, Nyenhuis DL, Gorelick PB. Predictors of survival in African American patients with AD, VaD or stroke without dementia. *Neurology* 2002; 59: 1146-1153.
215. Satz P. Brain reserve capacity on symptom onset after brain injury: a formulation and review of evidence for threshold theory. *Neuropsychology* 1993; 7: 273-295.
216. Teisberg B., Ferris SH, Shulamm E y cols. Longitudinal course normal aging and progressive dementia of the Alzheimer type: a prospective study of 106 subjects

- over a 3,6 year mean interval. *Prog Neuropsychopharmacol y Biol psychiat*, 1986; 10: 571-578.
217. Helmer C, Joly P, Letenneur L, Commenges D, Dartigues JF. Mortality with dementia: results from a French prospective community-based cohort. *Am J Epidemiol* 2001; 154: 642-8.
218. Rosa M. Sánchez. Estudio de los parámetros hemodinámicos en pacientes con leucoaraiosis mediante doppler transcraneal. Tesis Doctoral, Universidad Miguel Hernández, nov. 2001.
219. Helmer C, Lapane K, Gambassi G, Landi F, Sgadari A, Mor V, Bernabei R. Gender differences in predictors of mortality in nursing home residents with AD. *Neurology* 2001; 56: 650-4.
220. Lapane K, Gambassi G, Landi F, Sgadari A, Mor V, Bernabei R. Gender differences in predictors of mortality in nursing home residents with AD. *Neurology* 2001; 56: 650-4.
221. Gambassi G, Landi F, Lapane KL, Sgadari A, Mor V, Bernabei R on behalf of the SAGE study group. Predictors of mortality in patients with Alzheimer's disease living in nursing homes. *J Neurol Neurosurg Psychiatry* 1999; 67: 59-65.
222. Wang HS, Whanger AD. Brain impairment and longevity. En Palmore E, Jeffers (Eds.). London: Heath Lexington Boock, 1971.
223. Brookmeyer R, Corrada MM, Curriero FC, Kawas C. Survival following a diagnosis of Alzheimer's disease. *Arch Neurol* 2002; 59: 1764-1767.
224. Wolfson C, Wolfson DB, Asgharian M, M'Lan CE, Osbye T, Rockwood K et al for the clinical progresión of dementia study group. A reevaluation of survival after the onset of dementia. *N Engl J Med* 2001; 344: 1111-6.
225. Alberca R. Papel de la tacrina en la enfermedad de Alzheimer. Experiencia clínica en España. Resultados del estudio PAT. En: Papel de la Tacrina en el tratamiento de la enfermedad de Alzheimer. Barcelona Prous. Science, 1996; 27-43.

226. Gracon SI. Evaluation of tacrine hydrochloride (cognex) in two parallel-group studies. *Acta Neurol Scand* 1996; 114-122.
227. OttBR, Lapane KL. Tacrine therapy is associated with reduced mortality in nursing home residents with dementia. *J Am Geriatr Soc* 2002; 50: 35-40.
228. S.T. DeKosky. Neurobiología y biología molecular de la enfermedad de Alzheimer. *Rev. Neurol* 2002; 35: 752-760.
229. Kachaturian ZS. An overview of scientific issues associated with the heterogeneity of Alzheimer's disease. En : Boller F, y cols. (Eds.) *Heterogeneity of Alzheimer's disease*. Berlin Heidelberg: Springer-Verlag, 1992; 1-3.
230. R. Alberca. Heterogeneidad clínica de la enfermedad de Alzheimer. En: R. Alberca, S. López-Pousa (Eds.). *Enfermedad de Alzheimer y otras demencias*: Madrid, 200: 279-286.
231. Winblad B, Poritis N. Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine) *Int J Geriatr Psychiatry* 1999;14:135-46.
232. Agüero-Torres H, Fratiglioni L, Guo Z, Viitanen M, Winblad B. Prognostic factors in very old demented adults: a seven-year follow-up from a population based survey in Stockholm. *J Am Geriatr Soc* 1998; 46: 444-452.)
-